PubMed Health⌕ Search

Biomedical subjects

G Gartenberg

Publications and source records attributed to G Gartenberg.

11 recordsLinked to original sources

Essential thrombocytosis with the Philadelphia chromosome (Ph').

Essential thrombocytosis is a myeloproliferative disease not known to have consistent cytogenetic abnormalities. A 46-year-old black woman with essential thrombocytosis and a Philadelphia chromosome is reported. Iron deficiency and tuberculosis were present but when effectively treated did not result in resolution of thrombocytosis. Megakaryocytic hyperplasia of bone marrow, abnormal platelet function studies and a compatible clinical state suggested the diagnosis of essential thrombocytosis. The diagnostic criteria for other myeloproliferative diseases were not met. The Philadelphia chromosome was consistently obtained from bone marrow preparations. We conclude that the Philadelphia chromosome may be found in essential thrombocytosis as well as other, previously reported, myeloproliferative diseases.

Bone Marrow↗

Modifying empiric antibiotic prescribing: experience with one strategy in a medical residency program.

Initial experience with one strategy to modify selection of empiric antibiotic therapy by medical residents in presented. New orders for parenteral antibiotics written by residents before receiving culture results were randomly allocated to either a recommendation or a control group. Antibiotic orders from each group were compared with guidelines for antibiotic selection, and suggestions to change antibiotics were made only for orders from the recommendation group that did not match the guidelines. Recommendations for change appeared necessary for about 20% of the orders within each group. At follow-up, 78% of these orders had been changed as suggested in the recommendation group, whereas only 10% of the orders in the control group were changed (p less than 0.005). The mean difference in daily cost per order was a savings of $27.40 in the recommendation group and only $1.11 in the control group (p less than 0.01).

Anti-Bacterial Agents↗

Pharmacologic studies with cefaclor, a new oral cephalosporin.

Cefaclor, a new oral cephalosporin, was administered to 18 normal human volunteers in either single or multiple doses of 250 and 500 mg. Mean serum concentrations of 6.09 and 12.8 microgram/ml were achieved 1 hour after single oral doses of 250 and 500 mg, respectively. The serum concentrations declined rapidly and no drug was detected at 4 hours. Very high concentrations of cefaclor were found in urine during the first 8 hours after ingestion of the drug. Forty-three per cent of the total dose was excreted in urine during the first 8 hours. There was no accumulation of drug in serum during the multiple-dose studies.

Administration, Oral↗

Superior vena cava syndrome caused by invasive aspergillosis.

A 37-year-old man with blastic crisis of chronic myelogenous leukemia was admitted for chemotherapy. After treatment with an infusion of vincristine, he became leukopenic and febrile. Two episodes of gram-negative septicemia were treated with prolonged courses of antibiotics; however, fever persisted, and the patient developed the superior vena cava syndrome. Despite therapy with amphotericin B, the patient died. At autopsy a thrombus of Aspergillus was found completely occluding the superior vena cava.

Adult↗